Skip to content
Back to meeting Original
Christian Rolfo· @ChristianRolfo · X·· 1 day agoScore70
Body

Divarasib is improving the existing data in PFS , OS and ORR in KRAS G12C NSCLC in the Krascendo 1 trial. A really good news for our patients!
Congrats @FSkoulidis & team! Simultaneous publication in @NEJM
Excellent discussion @BenjaminBesseMD
@KRASKickers
@myESMO
#ESMO26

38 views · 1 like · 0 reposts · 0 replies

Conference abstracts

Source: Christian Rolfo · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.